June 08, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Three dosing levels of enpatoran each reduced disease activity among patients with skin manifestations of cutaneous or systemic lupus erythematosus, according to data published in Lancet Rheumatology.“The connection between interferon and SLE is an old story going back to the 1970s, when Hooks and his colleagues at the NIH published in the New England Journal of Medicine the results of
June 08, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Novel Lupus Drugs Continue to Shine in Extended Early Data

AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Groundbreaking therapy could revolutionise treatment for lupus

Can Hydroxychloroquine Reduce Risk of Progression to SLE in Patients With Incomplete Lupus?

Lupus put in remission by revolutionary immune system treatment

The FDA has granted breakthrough therapy designation to enpatoran for lupus with active skin manifestations, according to a press…

Find the latest Dermatology and Therapeutics news articles, videos, podcasts, and meeting coverage from medical experts and key…

For one of the two, the benefits continue long after treatment stops

DESTIN, Fla. — New treatments have improved outcomes in lupus, but preventing disease in the early stages remains elusive,…

CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…

The novel interleukin-17AA targeted molecule izokibep showed ACR50 response rates of more than 50% in psoriatic arthritis at 52…